Phase II Trial of Induction Cetuximab (IM-C225), Gemcitabine and Oxaliplatin, Followed by Radiotherapy With Concurrent Capecitabine, and Cetuximab, Followed by Maintenance Cetuximab and Gemcitabine for Patients With Locally Advanced Pancreatic Cancer.
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2013
At a glance
- Drugs Cetuximab (Primary) ; Capecitabine; Gemcitabine; Oxaliplatin
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 21 Mar 2013 Primary endpoint added as reported by ClinicalTrials.gov.
- 13 Apr 2011 Planned End Date changed from 1 Sep 2011 to 1 Sep 2012, according to ClinicalTrials.gov.
- 11 Aug 2010 Planned end date changed from 1 Sep 2010 to 1 Sep 2011 as reported by ClinicalTrials.gov.